John Johnson

Dr. John Johnson

Pathogen Biology Rajiv Gandhi Centre for Biotechnology

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2019 in Journal of Virology
Verified
Journal Article
Closed access
PDF file
UKUmerali Kunnakkadan
Umerali Kunnakkadan
JNJoydeep Nag
Joydeep Nag
NKNisha Asok Kumar
Nisha Asok Kumar
RMReshma Koolaparambil Mukesh
Reshma Koolaparambil Mukesh
SSSreenath Muraleedharan Suma
Sreenath Muraleedharan Suma
JJJohn Johnson
John Johnson
Among the innate immune sentinels, the complement system is a formidable first line of defense against pathogens, including viruses. Chandipura virus (CHPV), a neurotropic vesiculovirus of the family Rhabdoviridae, is a deadly human pathogen known to cause fatal encephalitis, especially among children. The nature of interaction and the effect of human complement on CHPV are unknown. Here, we report that CHPV is a potent activator of complement and, thus, is highly sensitive to complement proteins in normal human serum (NHS). Utilizing a panel of specific complement component depleted/reconstituted human serum, we have demonstrated that CHPV neutralization is C3, C4, and C1q dependent and independent of factor B, suggesting the importance of the classical pathway in limiting CHPV. Employing a range of biochemical approaches, we showed (i) a direct association of C1q to CHPV, (ii) deposition of complement proteins C3b, C4b, and C1q on CHPV, and (iii) virus aggregation. Depletion of C8, an important component of the pore-forming complex of complement, had no effect on CHPV, further supporting the finding that aggregation and not virolysis is the mechanism of virus neutralization. With no approved vaccines or treatment modalities in place against CHPV, insights into such interactions can be exploited to develop potent vaccines or therapeutics targeting CHPV. IMPORTANCE Chandipura virus is a clinically important human pathogen of the Indian subcontinent. The rapidity of death associated with CHPV infection in addition to the absence of an effective vaccine or therapeutics results in poor clinical prognosis. The biology of the virus and its interaction with the host immune system, including the complement system, are understudied. Our investigation reveals the susceptibility of CHPV to fluid phase complement and also dissects the pathway involved and the mechanism of virus neutralization. Direct binding of C1q, an important upstream component of the classical pathway of complement to CHPV, and the strong dependency on C1q for virus neutralization highlight the significance of identifying such interactions to better understand CHPV pathogenesis and devise strategies to target this deadly pathogen.

22 July 2016 in The FEBS Journal
Verified
Journal Article
Open access
PDF file
RGRoshna Lawrence Gomez
Roshna Lawrence Gomez
LJLeny Jose
Leny Jose
RRRanjit Ramachandran
Ranjit Ramachandran
SRSajith Raghunandanan
Sajith Raghunandanan
BMBalaji Muralikrishnan
Balaji Muralikrishnan
RKR. Ajay Kumar Kumar
R. Ajay Kumar Kumar
Rv3334 protein of Mycobacterium tuberculosis belongs to the MerR family of transcriptional regulators and is upregulated during hypoxia and other stress conditions. Employing GFP reporter constructs, mobility shift assays and ChIP assays, we demonstrate that Rv3334 binds to its own promoter and acts as an autorepressor. We were able to locate a 22 bp palindrome in its promoter that we show to be the cognate binding sequence of Rv3334. Using chase experiments, we could conclusively prove the requirement of this palindrome for Rv3334 binding. Recombinant Rv3334 readily formed homodimers in vitro, which could be necessary for its transcriptional regulatory role in vivo. Although the DNA‐binding activity of the protein was abrogated by the presence of certain divalent metal cations, the homodimer formation remained unaffected. In silico predictions and subsequent assays using GFP reporter constructs and mobility shift assays revealed that the expression of ketosteroid regulator gene (kstR), involved in lipid catabolism, is positively regulated by Rv3334. ChIP assays with aerobically grown M. tuberculosis as well as dormant bacteria unambiguously prove that Rv3334 specifically upregulates expression of kstR during dormancy. Our study throws light on the possible role of Rv3334 as a master regulator of lipid catabolism during hypoxia‐induced dormancy.

7 June 2022 in ACS Sensors
Verified
Journal Article
Closed access
DVDevika Vikraman
Devika Vikraman
RSRemya Satheesan
Remya Satheesan
MRMangaiyarkarasi Rajendran
Mangaiyarkarasi Rajendran
NKNisha Asok Kumar
Nisha Asok Kumar
JJJohn Johnson
John Johnson
KMKozhinjampara R. Mahendran
Kozhinjampara R. Mahendran

17 March 2020 in Journal of Virology
Verified
Journal Article
Closed access
JNJoydeep Nag
Joydeep Nag
RMReshma Koolaparambil Mukesh
Reshma Koolaparambil Mukesh
SSSreenath Muraleedharan Suma
Sreenath Muraleedharan Suma
UKUmerali Kunnakkadan
Umerali Kunnakkadan
NKNisha Asok Kumar
Nisha Asok Kumar
JJJohn Johnson
John Johnson
Chikungunya virus is a vector-borne pathogen of global significance. The morbidity associated with chikungunya virus (CHIKV) infection, neurovirulence and adaptability toAedes albopictus, necessitates a deeper understanding of the interaction of CHIKV with the host immune system. Here, we demonstrate that CHIKV is resistant to neutralization by one of the potent barriers of the innate immune arm, the complement system. Chikungunya virus showed marked resistance to complement despite activation and deposition of complement proteins. Interestingly the C3 component associated with the virion was found to be inactive C3b (iC3b), a key factor implicated in the pathogenesis and disease severity in the mouse model of Ross River virus infection. CHIKV also had an associated unique factor I-like activity that mediated the inactivation of C3b into iC3b. We have unraveled a smart strategy adopted by CHIKV to limit complement which has serious implications in viral dissemination, pathogenesis, and disease.

29 September 2020 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
NKNisha Asok Kumar
Nisha Asok Kumar
UKUmerali Kunnakkadan
Umerali Kunnakkadan
STSabu Thomas
Sabu Thomas
JJJohn Johnson
John Johnson
Complement, a part of the innate arm of the immune system, is integral to the frontline defense of the host against innumerable pathogens, which includes RNA viruses. Among the major groups of viruses, RNA viruses contribute significantly to the global mortality and morbidity index associated with viral infection. Despite multiple routes of entry adopted by these viruses, facing complement is inevitable. The initial interaction with complement and the nature of this interaction play an important role in determining host resistance versus susceptibility to the viral infection. Many RNA viruses are potent activators of complement, often resulting in virus neutralization. Yet, another facet of virus-induced activation is the exacerbation in pathogenesis contributing to the overall morbidity. The severity in disease and death associated with RNA virus infections shows a tip in the scale favoring viruses. Growing evidence suggest that like their DNA counterparts, RNA viruses have co-evolved to master ingenious strategies to remarkably restrict complement. Modulation of host genes involved in antiviral responses contributed prominently to the adoption of unique strategies to keep complement at bay, which included either down regulation of activation components (C3, C4) or up regulation of complement regulatory proteins. All this hints at a possible “hijacking” of the cross-talk mechanism of the host immune system. Enveloped RNA viruses have a selective advantage of not only modulating the host responses but also recruiting membrane-associated regulators of complement activation (RCAs). This review aims to highlight the significant progress in the understanding of RNA virus–complement interactions.

5 October 2021 in Molecular Therapy-Oncolytics
Verified
Journal Article
Open access
RMReshma Koolaparambil Mukesh
Reshma Koolaparambil Mukesh
AKAzeem Abdul Kalam
Azeem Abdul Kalam
JNJoydeep Nag
Joydeep Nag
VJVishnu Sunil Jaikumar
Vishnu Sunil Jaikumar
UKUmerali Kunnakkadan
Umerali Kunnakkadan
JJJohn Johnson
John Johnson
Chandipura virus (CHPV) is an emerging human pathogen of great clinical significance. In this study, we have investigated the susceptibility pattern of both normal and cancer cell lines of human origin to wild-type (wt) CHPV in order to explore the possibility of developing CHPV as an oncolytic vector (OV). Marked cytopathic effect along with enhanced virus output was observed in cancer cell lines (HeLa, A549, U-138, PC-3, and HepG2) in comparison to normal human adult dermal fibroblast (HADF) cells. At an MOI of 0.1, cancer cell lines were differentially susceptible to CHPV, with cells like HeLa and U-138 having pronounced cell death, while the PC-3 were comparatively resistant. All cell lines used in the study except U-138 restricted CHPV infection to varying degrees with IFN-β pre-treatment and supplementation of interferon (IFN) could neither activate the IFN signaling pathway in U-138 cells. Finally, U-138 tumor xenografts established in non-obese diabetic severe combined immunodeficiency (NOD/SCID) mice showed significant delay in tumor growth in the CHPV-challenged animals. Thus, targeted cytopathic effect in cancer cells at a very low dose with restricted replication in normal cells offers a rationale to exploit CHPV as an oncolytic vector in the future.